Citadel Advisors
ALXO icon

Citadel Advisors’s ALX Oncology ALXO Stock Holding History

Citadel Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.2K Sell
37,000
-29,900
-45% -$57K ﹤0.01% 12218
2025
Q4 		$75.6K Buy
66,900
+9,400
+16% +$14.2K ﹤0.01% 11835
2025
Q3 		$105K Buy
57,500
+3,700
+7% +$3.2K ﹤0.01% 11825
2025
Q2 		$22.3K Buy
53,800
+29,900
+125% +$15.1K ﹤0.01% 12079
2025
Q1 		$14.9K Sell
23,900
-9,300
-28% -$11.2K ﹤0.01% 13345
2024
Q4 		$55.4K Sell
33,200
-38,400
-54% -$59K ﹤0.01% 12286
2024
Q3 		$130K Buy
71,600
+36,800
+106% +$137K ﹤0.01% 10750
2024
Q2 		$210K Buy
34,800
+25,700
+282% +$316K ﹤0.01% 9824
2024
Q1 		$101K Sell
9,100
-17,100
-65% -$240K ﹤0.01% 11339
2023
Q4 		$390K Buy
26,200
+12,400
+90% +$118K ﹤0.01% 8621
2023
Q3 		$66.2K Sell
13,800
-6,200
-31% -$33.6K ﹤0.01% 11397
2023
Q2 		$150K Buy
20,000
+16,400
+456% +$107K ﹤0.01% 10336
2023
Q1 		$16.3K Sell
3,600
-1,600
-31% -$12.1K ﹤0.01% 13214
2022
Q4 		$58.6K Sell
5,200
-37,000
-88% -$416K ﹤0.01% 11940
2022
Q3 		$404K Sell
42,200
-46,800
-53% -$545K ﹤0.01% 8924
2022
Q2 		$720K Buy
89,000
+76,400
+606% +$832K ﹤0.01% 7792
2022
Q1 		$213K Buy
12,600
+800
+7% +$13.7K ﹤0.01% 11367
2021
Q4 		$254K Sell
11,800
-4,700
-28% -$203K ﹤0.01% 11309
2021
Q3 		$1.22M Buy
16,500
+1,400
+9% +$93.3K ﹤0.01% 7630
2021
Q2 		$826K Sell
15,100
-6,700
-31% -$401K ﹤0.01% 8856
2021
Q1 		$1.61M Buy
+21,800
New +$1.72M ﹤0.01% 6932

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Citadel Advisors's ALXO Position: Q1 2026 in Review

Citadel Advisors sold out of ALX Oncology (ALXO) in Q1 2026, closing a stake of 56,732 shares — an estimated $108K sold.

Citadel Advisors first reported a position in ALXO in Q4 2020 and held it in 18 quarters. The position peaked at $24.4M in Q4 2020. 69 funds tracked by Wall St. Rank hold ALXO as of Q1 2026.

  • Citadel Advisors reported no remaining ALX Oncology position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 56,732 ALX Oncology shares in Q1 2026, an estimated $108K.
  • Citadel Advisors first reported a position in ALX Oncology in Q4 2020 and held it in 18 quarters.
  • Citadel Advisors's ALX Oncology position peaked at $24.4M in Q4 2020.
  • 69 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.